阿巴洛帕肽皮下注射通过骨小梁评分评估改善骨小梁微结构:一项24周随机临床试验
这项2期试验的事后分析纳入222名55至85岁绝经后骨质疏松女性,随机接受阿巴洛帕肽皮下注射(20、40或80 μg)、特立帕肽皮下注射(20 μg)或安慰剂治疗24周。在138名DXA设备兼容TBS软件的受试者中,阿巴洛帕肽各剂量组和特立帕肽组的骨小梁评分较基线显著升高,而安慰剂组下降,且各治疗组均显著高于安慰剂组,阿巴洛帕肽80 μg组显著高于特立帕肽组。
要点
- 阿巴洛帕肽皮下注射20、40、80 μg组24周时TBS较基线分别升高2.27%、3.14%、4.21%,特立帕肽组升高2.21%,安慰剂组下降1.08%。
- 校正年龄、BMI和基线TBS后,各治疗组TBS升高均显著高于安慰剂组(p<0.0001)。
- 阿巴洛帕肽三个剂量与安慰剂间观察到剂量反应(p=0.02),80 μg组TBS升高显著大于特立帕肽组(p<0.03)。
核心结论
- 结果与阿巴洛帕肽皮下注射通过TBS评估改善腰椎骨骼微结构的效应一致。
研究设计与样本
- 这是对一项2期试验的事后分析,该试验纳入222名55至85岁绝经后骨质疏松女性,随机接受阿巴洛帕肽皮下注射(20、40或80 μg)、特立帕肽皮下注射(20 μg)或安慰剂治疗24周。
- TBS从138名DXA设备兼容TBS软件的女性的腰椎双能X线吸收法图像中测量,评估时间点为基线、12周和24周。
- 组间差异采用广义估计方程校正相关基线特征,并进行预设的最小显著变化分析。
主要发现
- 24周后,阿巴洛帕肽皮下注射20、40、80 μg组TBS较基线分别显著升高2.27%、3.14%、4.21%,特立帕肽组升高2.21%(每组p<0.05)。
- 安慰剂组TBS下降1.08%。
- 校正年龄、BMI和基线TBS后,24周时各治疗组TBS升高均显著高于安慰剂组(每组p<0.0001)。
- 24周时在阿巴洛帕肽皮下注射三个剂量和安慰剂间观察到剂量反应(p=0.02)。
- 阿巴洛帕肽皮下注射80 μg组TBS升高显著大于特立帕肽组(p<0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to one of three different doses of abaloparatide-SC, subcutaneous teriparatide, or placebo for 24 weeks, abaloparatide-SC resulted in improvements in skeletal microarchitecture as measured by the trabecular bone score. INTRODUCTION: Subcutaneous abaloparatide (abaloparatide-SC) increases total hip and lumbar spine bone mineral density and reduces vertebral and non-vertebral fractures. In this study, we analyzed the extent to which abaloparatide-SC improves skeletal microarchitecture, assessed indirectly by trabecular bone score (TBS). METHODS: This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks. TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible. Assessments were made at baseline, 12 and 24 weeks. Between-group differences were assessed by generalized estimating equations adjusted for relevant baseline characteristics, and a pre-determined least significant change analysis was performed. RESULTS: After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each). The TBS in the placebo group declined by 1.08%. The TBS increase in each treatment group was significantly higher than placebo at 24 weeks (p < 0.0001 for each) after adjustment for age, BMI, and baseline TBS. A dose-response was observed at 24 weeks across the three doses of abaloparatide-SC and placebo (p = 0.02). The increase in TBS in the abaloparatide-SC 80 μg group was significantly greater than TPTD (p < 0.03). CONCLUSIONS: These results are consistent with an effect of abaloparatide-SC to improve lumbar spine skeletal microarchitecture, as assessed by TBS.
引用
- Bilezikian JP, Hattersley G, Fitzpatrick LA, et al. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2017. PMID: 29167971. doi:10.1007/s00198-017-4304-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。